Skip to main content

Oramed Pharmaceuticals Inc.

ORMP
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001176309

In the last 90 days, Oramed Pharmaceuticals Inc. insiders filed 0 open-market purchases and 2 sales; 84 institutions reported holding it in 13F filings for Q2 2026, worth $80.7M in total; no superinvestor holds it.

Q3 2024 vs. Q2 2024

How the institutions holding Oramed Pharmaceuticals Inc. changed between Q2 2024 and Q3 2024.

All holders in Q3 2024All holders in Q2 2024

13F holders of ORMP: Q2 2024 compared with Q3 2024
MeasureQ2 2024Of which not filed for Q3 2024Q3 2024Change
Holders59155−3
Shares5.93M89.7K6.96M+1.12M (+19.1%)
Value$15.2M$230.5K$17.0M+$1.96M (+13.1%)

1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.

New holders (8)

Institutions that held Oramed Pharmaceuticals Inc. at the end of Q3 2024 but not at the end of Q2 2024.

Institutions new to ORMP in Q3 2024
InstitutionSharesValue% of portfolio
Connor, Clark & Lunn Investment Management Ltd.111,519$272.1K0.00%
BlackRock, Inc.92,009$224.5K0.00%
Marshall Wace, LLP22,527$55.0K0.00%
Citadel Advisors LLC21,402$52.2K0.00%
Prelude Capital Management, LLC14,435$35.2K0.00%
FMR LLC1,500$3.66K0.00%
Nordwand Advisors, LLC1,000$2.44K0.00%
Jones Financial Companies LLLP572$1.42K0.00%

Sold out (11)

Institutions that held Oramed Pharmaceuticals Inc. at the end of Q2 2024 and filed for Q3 2024 without it.

Not filed for Q3 2024 yet (1)

Institutions that held Oramed Pharmaceuticals Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding ORMP in Q2 2024 that haven't filed for Q3 2024
InstitutionShares, Q2 2024Value, Q2 2024
BlackRock Inc.89,706$230.5K